Gilead’s Yeztugo drug for HIV prevention in adults gets FDA nod
HQ Team June 19, 2025: Gilead Sciences, Inc.’s twice-yearly injectable drug for the prevention of HIV in adults and adolescents got approval from.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
HQ Team June 19, 2025: Gilead Sciences, Inc.’s twice-yearly injectable drug for the prevention of HIV in adults and adolescents got approval from.
HQ Team June 4, 2025: British-Swedish AstraZeneca Plc.’s investigational pill to treat an advanced breast cancer has reduced the chance of worsening the.
The US regulator has granted a breakthrough therapy designation to British-Swedish AstraZeneca and Japan’s Daiichi Sankyo experimental drug for treating a certain type.
AstraZeneca and Daiichi Sankyo got a priority review from the Food and Drug Administration for their Enhertu drug to treat a form of.